Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04832425


Additional trial details provided through ANZCTR are available at the end of this record.


Registration number
NCT04832425
Ethics application status
Date submitted
19/03/2021
Date registered
5/04/2021
Date last updated
21/07/2022

Titles & IDs
Public title
A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder
Scientific title
A Phase 2/3 Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of PRAX-114 in Participants With Major Depressive Disorder
Secondary ID [1] 0 0
PRAX-114-213
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Major Depressive Disorder 0 0
Condition category
Condition code
Mental Health 0 0 0 0
Depression

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - PRAX-114
Treatment: Drugs - Placebo

Experimental: PRAX-114 - 40 mg PRAX-114 once daily

Placebo comparator: Placebo - Placebo once daily


Treatment: Drugs: PRAX-114
40 mg once daily

Treatment: Drugs: Placebo
Placebo once daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from baseline in 17-Item Hamilton Depression Rating Scale (HAM-D17) total score at Day 15
Timepoint [1] 0 0
15 days
Secondary outcome [1] 0 0
Change from baseline in HAM-D17 total score at Day 29
Timepoint [1] 0 0
29 days
Secondary outcome [2] 0 0
Change from baseline in HAM-D17 total score at all other time points
Timepoint [2] 0 0
8 days, 22 days, 36 days, and 43 days
Secondary outcome [3] 0 0
Change from baseline in Clinical Global Impression-Severity (CGI-S) score at Day 15 and all other time points
Timepoint [3] 0 0
8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
Secondary outcome [4] 0 0
Clinical Global Impression-Improvement (CGI-I) score at Day 15 and all other time points
Timepoint [4] 0 0
8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
Secondary outcome [5] 0 0
HAM-D17 response (reduction from baseline score of =50%) at Day 15, Day 29, and all other time points
Timepoint [5] 0 0
8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
Secondary outcome [6] 0 0
HAM-D17 remission (total score of =7) at Day 15, Day 29, and all other time points
Timepoint [6] 0 0
8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
Secondary outcome [7] 0 0
Change from baseline in the Symptoms of Depression Questionnaire (SDQ) total and sub-scale scores at Day 15 and all other time points
Timepoint [7] 0 0
8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
Secondary outcome [8] 0 0
Patient Global Impression-Improvement (PGI-I) score at Day 15 and all other time points
Timepoint [8] 0 0
8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
Secondary outcome [9] 0 0
Change from baseline in the Work and Social Adjustment Scale (WSAS) at Day 15 and all other time points
Timepoint [9] 0 0
8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
Secondary outcome [10] 0 0
Change from baseline in the 12-Item Short Form Survey (SF-12) at Day 15 and all other time points
Timepoint [10] 0 0
8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
Secondary outcome [11] 0 0
Incidence and severity of Adverse Events (AE)
Timepoint [11] 0 0
43 days
Secondary outcome [12] 0 0
Incidence of AEs by preferred term
Timepoint [12] 0 0
Up to 43 days
Secondary outcome [13] 0 0
Incidence of Columbia-Suicide Severity Rating Scale (C-SSRS) measured suicidal ideation or behavior
Timepoint [13] 0 0
Up to 43 days

Eligibility
Key inclusion criteria
1. Recurrent MDD diagnosis with a current episode duration of at least 8 weeks and no more than 24 months.
2. HAM-D17 total score of =23 at Screening and Baseline.
3. Body mass index (BMI) between 18 and 38 kg/m2 (inclusive).
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Lifetime history of seizures, including febrile seizures.
2. Neurodegenerative disorder (eg, Alzheimer's disease, Parkinson's disease, multiple sclerosis, or Huntington's disease).
3. Lifetime history of bipolar disorder, a psychotic disorder (eg, schizophrenia or schizoaffective disorder), or obsessive compulsive disorder or a history of a psychotic mood episode in last 2 years.
4. Any current psychiatric disorder (other than MDD).
5. Lifetime history of treatment resistant depression.
6. Received electroconvulsive therapy (ECT) or vagus nerve stimulation (VNS) within the last year or transcranial magnetic stimulation (TMS) within the last 6 months prior to Screening.
7. Daily consumption of more than 2 standard alcohol-containing beverages for males or more than 1 standard alcohol-containing beverages for females.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/03/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
5/05/2022
Sample size
Target
Accrual to date
Final
216
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Praxis Research Site - Noble Park
Recruitment postcode(s) [1] 0 0
3174 - Noble Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Missouri
Country [9] 0 0
United States of America
State/province [9] 0 0
Nevada
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
Tennessee
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
United States of America
State/province [16] 0 0
Virginia
Country [17] 0 0
United States of America
State/province [17] 0 0
Washington

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Praxis Precision Medicines
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of PRAX-114 in participants with moderate to severe major depressive disorder (MDD). Participants will be randomized to receive 28 days of either 40 mg PRAX-114 or placebo in a 1:1 ratio.
Trial website
https://clinicaltrials.gov/study/NCT04832425
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
VP, Clinical Development
Address 0 0
Praxis Precision Medicines
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04832425

Additional trial details provided through ANZCTR
Accrual to date
Recruiting in Australia
Recruitment state(s)
QLD,VIC
Funding & Sponsors
Primary sponsor
Commercial sector/Industry
Primary sponsor name
Praxis Precision Medicines Australia, Pty Ltd
Primary sponsor address
Tower Two Collins Square, Level 36
727 Collins St, Docklands, Vic, 3008
Primary sponsor country
Australia
Ethics approval
Ethics application status
Approved
 
Public notes

Contacts
Principal investigator
Title 217 0
Prof
Name 217 0
David Barton
Address 217 0
1 Beck Court Noble Park, Vic, 3174
Country 217 0
Australia
Phone 217 0
+61 3 9546 0009
Fax 217 0
Email 217 0
[email protected]
Contact person for public queries
Title 218 0
Dr
Name 218 0
Bernard Ravina
Address 218 0
Praxis Precision Medicines One Broadway, 16th Floor Cambridge, MA 02142
Country 218 0
United States of America
Phone 218 0
+1 617 300 8460
Fax 218 0
Email 218 0
[email protected]
Contact person for scientific queries
Title 219 0
Dr
Name 219 0
Bernard Ravina
Address 219 0
Praxis Precision Medicines One Broadway, 16th Floor Cambridge, MA 02142
Country 219 0
United States of America
Phone 219 0
+1 617 300 8460
Fax 219 0
Email 219 0
[email protected]